Ironwood and forest to present linaclotide results from phase 2b and phase 3 trials in patients with irritable bowel syndrome with constipation or chronic constipation
Forest Laboratories, 10/28/2011
Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. announced they will be presenting additional linaclotide results from four pivotal Phase 3 trials and one Phase 2b study in patients with either irritable bowel syndrome with constipation (IBS–C) or chronic constipation (CC) at the American College of Gastroenterology (ACG) 2011 Annual Scientific Meeting being held in Washington, DC from October 2011 to November 2011. Linaclotide is an investigational guanylate cyclase type–C (GC–C) agonist for the treatment of IBS–C and CC. Positive results from each of these trials have been reported previously.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.